ReviewArquivos de neuro-psiquiatria2026
The emerging role of high-intensity focused ultrasound (HIFU) as a symptomatic treatment for Parkinson's disease and essential tremor: a narrative review.
Review in Arquivos de neuro-psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: The high-intensity focused ultrasound (HIFU) technique has become precise, incisionless, and ablative for treating essential tremor (ET) and Parkinson's disease (PD), driven by advances in magnetic resonance imaging (MRI) thermometry and tractography. The current review integrates the main clinical outcomes associated with established and emerging HIFU targets, synthesizing efficacy data, adverse effect (AE) patterns, and procedural characteristics relevant to clinical decision-making. In ET, ventral intermediate nucleus (VIM) thalamotomy results in tremor reductions ranging from 56 to 81%, with a long-term sustained benefit of approximately 73%. In tremor-dominant PD (TdPD), VIM ablation achieves tremor suppression of approximately 62%. Comparatively, HIFU-guided subthalamotomy provides broader motor benefits, with 53 to 57.8% improvement in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS III), as well as significant reductions in rigidity and bradykinesia. Pallidotomy improves "off" state motor symptoms and dyskinesias, whereas pallidothalamic tractotomy leads to 52% global motor improvement and 91% tremor reduction. The AEs vary according to the targets. In VIM procedures, gait imbalance (16-40%) and sensory disturbances (9-26%) predominate, along with dysarthria and dysmetria. Lesions to the subthalamic nucleus (STN) are most commonly associated with dysarthria (10-26%) and gait instability (15-48%). Procedures targeting the globus pallidus internus (GPi) or pallidothalamic tract (PTT) may also present with gait instability or dysarthria, which are generally mild and transient. Although the SDR has historically limited eligibility, recent evidence demonstrates that patients with SDR ≤ 0.40 may still experience meaningful improvement, supporting more individualized selection. In the current therapeutic landscape, HIFU offers immediate clinical benefits, absence of implanted hardware, and simplified recovery, positioning it as an alternative or complementary therapy to deep brain stimulation (DBS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.